Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Krystal Biotech, Inc. (KRYS)
:KRYS
KRYS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$107.50 - $219.34
Previous CloseN/A
Volume44.50K
Average Volume (3M)265.30K
Market Cap
$5.26B
Enterprise Value$4.86B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)103.3
Beta1.26
Next Earnings
May 12, 2025EPS Estimate
1.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.77
Shares Outstanding28,806,078
10 Day Avg. Volume295,674
30 Day Avg. Volume265,296
Standard Deviation0.15
R-Squared0.09
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)20.98
Price to Cash Flow (P/CF)21.50
P/FCF Ratio21.90
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit102.14
Enterprise Value/Ebitda75.98
Forecast
1Y Price Target
$212.40Price Target Upside16.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Krystal Biotech News
PremiumCompany Announcements
Krystal Biotech Earnings Call: Optimism Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
Financial HealthKRYS reported $749.6M in cash and investments at the end of the quarter, showcasing strong financial health.
Market AcceptanceCrossing 500 reimbursement approvals is impressive, indicating solid market acceptance.
Bears Say
Patient Compliance4Q24 Vyjuvek patient compliance was 85%, down from 87% in the previous quarter due to breaks in therapy.
---
Ownership Overview
22.63% Insiders
34.60% Mutual Funds
0.05% Other Institutional Investors
18.82% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KRYS FAQ
What was Krystal Biotech, Inc.’s price range in the past 12 months?
Krystal Biotech, Inc. lowest stock price was $107.50 and its highest was $219.34 in the past 12 months.
What is Krystal Biotech, Inc.’s market cap?
Krystal Biotech, Inc.’s market cap is $5.26B.
When is Krystal Biotech, Inc.’s upcoming earnings report date?
Krystal Biotech, Inc.’s upcoming earnings report date is May 12, 2025 which is in 79 days.
How were Krystal Biotech, Inc.’s earnings last quarter?
Krystal Biotech, Inc. released its earnings results on Feb 19, 2025. The company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.184 by $0.336.
Is Krystal Biotech, Inc. overvalued?
According to Wall Street analysts Krystal Biotech, Inc.’s price is currently Undervalued.
Does Krystal Biotech, Inc. pay dividends?
Krystal Biotech, Inc. does not currently pay dividends.
What is Krystal Biotech, Inc.’s EPS estimate?
Krystal Biotech, Inc.’s EPS estimate is 1.5.
How many shares outstanding does Krystal Biotech, Inc. have?
Krystal Biotech, Inc. has 28,806,078 shares outstanding.
What happened to Krystal Biotech, Inc.’s price movement after its last earnings report?
Krystal Biotech, Inc. reported an EPS of $1.52 in its last earnings report, beating expectations of $1.184. Following the earnings report the stock price went up 12.432%.
Which hedge fund is a major shareholder of Krystal Biotech, Inc.?
Currently, no hedge funds are holding shares in KRYS
---
Krystal Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$212.40 (16.31% Upside)
$212.40 (16.31% Upside)
Blogger Sentiment
Bullish
KRYS Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 4.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $106.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.6%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
63.57%
12-Months-Change
Fundamentals
Return on Equity
6.38%
Trailing 12-Months
Asset Growth
24.29%
Trailing 12-Months
Company Description
Krystal Biotech, Inc.
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.
---
KRYS Company Deck
---
KRYS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance, successful VYJUVEK launch, and robust pipeline developments. However, challenges in patient compliance, operational delays, and increased expenses were noted. The company's strategic plans for global expansion and future growth provide a positive outlook.Read More>---
KRYS Stock 12 Month Forecast
Average Price Target
$212.40
▲(16.31% Upside)
Technical Analysis
Sarepta Therapeutics
―
Bluebird Bio
―
uniQure
―
Editas Medicine
―
Intellia Therapeutics
―
Best Analysts Covering KRYS
1 Year
1 Year Success Rate
13/15 ratings generated profit
1 Year Average Return
+45.80%
reiterated a buy rating 3 days ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +45.80% per trade.
---